This drug is presently undergoing Phase I/II clinical trial investigations (http://clinicaltrials.gov/ct2/show/NCT01970865) in ROS1 and ALK fusion-positive NSCLC patients13, 15, 16, 17, 18, 19, 20, 21. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.